Clinical comparison of extended-release divalproex versus delayed-release divalproex: Pooled data analyses from nine trials

Epilepsy and Behavior

Volumn 5, Issue 5, 2004, Pages 746-751

  Smith, Michael C ^a   Centorrino, Franca ^b   Welge, Jeffrey A ^c   Collins, Michelle A ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Bipolar disorder; Divalproex; Epilepsy; Extended release; Valproate

Indexed keywords

ANTIMIGRAINE AGENT; TRANQUILIZER; VALPROATE SEMISODIUM; ANTICONVULSIVE AGENT; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; DRUG RELEASE; DRUG TOLERABILITY; EPILEPSY; FREQUENCY ANALYSIS; GASTROINTESTINAL DISEASE; HAIR LOSS; HUMAN; MANIA; MCNEMAR TEST; META ANALYSIS; MIGRAINE; SEIZURE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREMOR; WEIGHT GAIN; ADOLESCENT; ADULT; AGED; CHILD; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; FEMALE; MALE; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 15344348832     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2004.07.007     Document Type: Article

References (37)

1. O. Devinsky Patients with refractory seizures N. Engl. J. Med. 340 1999 1565-1570
2. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4)
3. W.A. Hauser D.C. Hersdorffer Epilepsy: Frequency, causes and consequences 1990 Demos New York
4. R.C. Kessler K.A. McGonagle S. Zhao et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States Arch. Gen. Psychiatry 51 1994 8-19
5. M.J. Brodie J.A. French Management of epilepsy in adolescents and adults Lancet 356 2000 323-329
6. S. Karceski M. Morrell D. Carpenter The expert consensus guideline series, treatment of epilepsy Epilepsy Behav. 2 2001 A1-50
7. A.H. Heller P. Chesterman R.D.C. Elwes et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomized comparative monotherapy trial J. Neurol. Neurosurg. Psychiatry 58 1995 44-50
8. A. Beydoun J.C. Sackellares V. Shu et al. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: A double-blind, concentration-response design clinical trial Neurology 48 1997 182-188
9. C.L. Bowden A.M. Brugger A.C. Swann et al. For the Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania JAMA 271 1994 918-924
10. C.L. Bowden J.R. Calabrese S.L. McElroy et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder Arch. Gen. Psychiatry 57 2000 481-489
11. H.G. Pope Jr. S.L. McElroy P.E. Keck Jr. J.I. Hudson Valproate in the treatment of acute mania: A placebo-controlled study Arch. Gen. Psychiatry 48 1991 62-68
12. Sachs G, Altshuler L, Ketter T, et al. Divalproex versus placebo for the treatment of bipolar depression [abstract]. Paper presented at: American College of Neuropsychopharmacology Annual Meeting; 2001
13. DEPAKOTE® ER tablets, Abbott Laboratories. In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co. Inc.; 2002, pp. 436-40
14. TEGRETOL® XR, Novartis Pharmaceuticals Corporation, Basel, Switzerland, In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co. Inc.; 2002, pp. 2404-7
15. LITHOBID®, Solvay S.A., Brussels, Belgium. In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co. Inc.; 2002, pp. 3255-6
16. ESKALITH® CR, GlaxoSmithKline, Research Triangle Park, NC, USA. In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co. Inc.; 2002, pp. 1527-8
17. J.W. Wheless V. Venkataraman New formulations of drugs in epilepsy Expert Opin. Pharmacother. 1 1999 49-60
18. CARBATROL®, Shire Pharmaceuticals Group, Hampshire, UK. In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co. Inc.; 2002, pp. 3234-6
19. DEPAKOTE® tablets, Abbott Laboratories, Abbott Park, IL, USA. In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co. Inc.; 2002, pp. 430-6
20. S. Dutta Y. Zhang D. Selness et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers Epilepsy Res. 49 2002 1-10
21. K.S. Sommerville S. Dutta V. Biton Y. Zhang J.C. Cloyd B. Uthman Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs Clin. Drug Invest. 23 2003 661-670
22. D. Zielinski M. Smith The use of the extended-release formulation of divalproex sodium in patients with epilepsy [abstract 1.291] Epilepsia 42 Suppl. 7 2001 92
23. N.M. Thompson K. Yu S.M. Mills C.M. Cunanan et al. Safety and efficacy of divalproex sodium extended-release (Depakote® ER) in pediatric neurology [abstract 1.273] Epilepsia 42 Suppl. 7 2001 87
24. Longo LP. Depakote extended release for psychiatric patients experiencing side effects from Depakote [abstract]. Paper presented at: American Psychiatric Association Annual Meeting; 2001
25. Minirth F, Neal V. Assessment of compliance and side effects in patients switched from divlaproex sodium delayed-release to divalproex sodium extended-release [abstract]. Paper presented at: Institute on Psychiatric Services; 2002
26. P. McCabe N.C. Michel C.D. McNew Rapid conversion from delayed-release valproic acid (VPA) to extended-release VPA: Clinical and pharmacokinetic observations [abstract 1.284] Epilepsia 42 Suppl. 7 2001 90
27. Uthman BM, Biton V, Dutta S, et al. Comparison of the bioavailability of a Depakote® extended-release formulation relative to the Depakote® delayed-release tablet formulation in adult patients with epilepsy on the Depakote® delayed-release tablet formulation and an enzyme-inducing anti-epileptic drug [abstract]. Paper presented at: Fifth European Congress of Epileptology; Madrid, Spain; 2002
28. M. Thibault W.T. Blume J.-M. Saint-Hilaire R. Zakhari K.W. Sommerville Divalproex extended-release versus the original divalproex tablet: results of a randomized crossover study of well-controlled epileptic patients with primary generalized seizures Epilepsy Res. 50 2002 243-249
29. R.L. Horne C. Cunanan Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium J. Clin. Psychopharmacol. 23 2003 1-6
30. F. Centorrino J.P. Kelleher J.M. Berry et al. Pilot comparison of extended release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders Am. J. Psychiatry 160 2003 1348-1350
31. S. Dutta Y. Zhang J.M. Conway et al. Divalproex-ER pharmacokinetics in older children and adolescents Pediatr. Neurol. 30 2004 330-337
32. F.G. Freitag S.D. Collins H.A. Carlson et al. For the Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis Neurology 58 2002 1652-1659
33. R. Hering A. Kuritzky Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo Cephalalgia 12 1992 81-84
34. N.T. Mathew J.R. Saper S.D. Silberstein et al. Migraine prophylaxis with divalproex Arch. Neurol. 52 1995 281-286
35. J. Klapper for the Divalproex Sodium Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: A dose-controlled study Cephalalgia 17 1997 103-108
36. C. Bouchet F. Guillemin S. Briancon Nonspecific effects in longitudinal studies impact on quality of life measures J. Clin. Epidemiol. 1 1996 15-20
37. Dutta S, Reed RC, Divalproex to divalproex-ER dose conversion: Analysis of five distinct studies and dosing recommendations [abstract W5223]. AAPS PharmSci, 2003, 4(4). Available from: http://www.aapspharmsci.org/